drugset / Trial / NCT04914767

Nigella 5 in the Treatment of SARS COV2 (COVID-19)

NCT04914767 ↗

Phase 1 Completed 500 enrolled Hôpital Universitaire Sahloul
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The world is currently facing a crisis because of this potentially fatal situation of the COVID-19 epidemic without proven efficacy for any drug treatment, while the vaccination is not yet. This epidemic is caused by a new betacorona virus, now called SARS-CoV-2. The most common symptoms reported are fever, cough or chest tightness, and dyspnea. Most cases have a mild course

Timeline

Start
2021-03-01
Primary completion
2021-10-30
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject NP-101 Traditional medicine (herbal / TCM) — Oral

Indications